Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient took three doses of Vivotif on consecutive days instead of every other day; Case reference number US-BN-2025-001902 is a spontaneous case initially received from other health professional via Bavarian Nordic (reference number: CASE-001022) on 03-Dec-2025 and concerns a male patient of unknown age. The patient's medical history and concomitant medication details were not provided. On unknown dates, the patient took the first three doses of the Vivotif on consecutive days instead of every other day (batch number: unknown) at an unknown dose, route of administration for an unknown indication (explicitly coded as 'inappropriate schedule of vaccine administered') At the time of the initial report, it was unknown if the patient experienced any adverse events due to the Vivotif vaccine. No further information was provided.; Reporter's Comments: A male patient of unknown age took the first three doses of the Vivotif on consecutive days instead of every other day, for an unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to the Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unknown age took the first three doses of the Vivotif on consecutive days instead of every other day, for an unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to the Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE.